Author: "Ghesquières, Hervé" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Ghesquières, Hervé"' showing total 671 results

Start Over Author "Ghesquières, Hervé"

671 results on '"Ghesquières, Hervé"'

201. Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT

Author: Rossi, Cédric, primary, Mounier, Morgane, additional, Brice, Pauline, additional, Safar, Violaine, additional, Nicolas-Virelizier, Emmanuelle, additional, Rey, Philippe, additional, Stamatoullas-Bastard, Aspasia, additional, Alcantara, Marion, additional, Chauchet, Adrien, additional, Reboursière, Emilie, additional, Filliatre, Lauriane, additional, Perrot, Aurore, additional, Garciaz, Sylvain, additional, Salles, Gilles, additional, Coiffier, Bertrand, additional, Ghesquières, Hervé, additional, and Casasnovas, René-Olivier, additional
Published: 2017
Full Text: View/download PDF

202. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma

Author: Maurer , Matthew J, Jais , Jean-Philippe, Ghesquières , Hervé, Witzig , Thomas E, Hong , Fangxin, Haioun , Corinne, Thompson , Carrie A, Thieblemont , Catherine, Micallef , Ivana N, Porrata , Luis F, Ribrag , Vincent, Nowakowski , Gregorz S, Casasnovas , Olivier, Bologna , Serge, Li , Franck, Morrison , Vicki A, Peterson , Bruce A, Macon , William R, Copie-Bergman , Christiane, Feldman , Andrew L, Syrbu , Sergei I, Kurtin , Paul J, Gascoyne , Randy D, Li , Hailun, Allmer , Cristine, Kahl , Brad S, Ansell , Stephen M, Slager , Susan L, Link , Brian K, Salles , Gilles, Habermann , Thomas M, Tilly , Hervé, Cerhan , James R, Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Léon Bérard [Lyon], Ecole Polytechnique Fédérale de Lausanne ( EPFL ), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), The hospital for tropical diseases, Oxford University Clinical Research Unit, Oxford University Clinical Research Unit [Ho Chi Minh City]-Oxford University Clinical Research Unit [Ho Chi Minh City], Centre for Tropical Medicine, University of Oxford [Oxford], Hématologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy ( IGR ) -Institut Gustave Roussy ( IGR ), Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), University of Guelph, Groupe Henri Mondor-Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Institut des Sciences Moléculaires ( ISM ), Université Montesquieu - Bordeaux 4-Université Sciences et Technologies - Bordeaux 1-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Centre National de la Recherche Scientifique ( CNRS ), Service de Radio-Oncologie [Lyon], Hospices Civils de Lyon ( HCL ) -Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), and Hospices Civils de Lyon ( HCL )
Subjects: Adult, Aged, 80 and over, Male, Models, Statistical, Adolescent, Kaplan-Meier Estimate, Middle Aged, Disease-Free Survival, Article, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Young Adult, Risk Factors, Multivariate Analysis, Humans, Female, Immunotherapy, Lymphoma, Large B-Cell, Diffuse, Prospective Studies, Precision Medicine, Aged
Abstract: International audience; We recently defined event-free survival at 24 months (EFS24) as a clinically relevant outcome for patients with DLBCL. Patients who fail EFS24 have very poor overall survival, while those who achieve EFS24 have a subsequent overall survival equivalent to that of the age- and sex-matched general population. Here, we develop and validate a clinical risk calculator (IPI24) for EFS24. Model building was performed on a discovery dataset of 1,348 patients with DLBCL and treated with anthracycline-based immunochemotherapy. A multivariable model containing age, Ann Arbor stage, normalized serum LDH, ALC, ECOG performance status, bulky disease, and sex was identified. The model was then applied to an independent validation dataset of 1,177 DLBCL patients. The IPI24 score estimates the probability of failing to achieve the EFS24 endpoint for an individual patient. The IPI24 model showed superior discriminatory ability (c-statistic = 0.671) in the validation dataset compared to the IPI (c-statistic = 0.649) or the NCCN-IPI (c-statistic = 0.657). After recalibration of the model on the combined dataset, the median predicted probability of failing to achieve EFS24 was 36% (range, 12-88%), and the IPI24 showed an EFS24 gradient in all IPI groups. The IPI24 also identified a significant percentage of patients with high risk disease, with over 20% of patients having a 50% or higher risk of failing to achieve EFS24. The IPI24 provides an individual patient level probability of achieving the clinically relevant EFS24 endpoint. It can be used via electronic apps.
Published: 2015

203. Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways.

Author: Kleinstern, Geffen, Yan, Huihuang, Hildebrandt, Michelle A T, Vijai, Joseph, Berndt, Sonja I, Ghesquières, Hervé, McKay, James, Wang, Sophia S, Nieters, Alexandra, Ye, Yuanqing, Monnereau, Alain, Brooks-Wilson, Angela R, Lan, Qing, Melbye, Mads, Jackson, Rebecca D, Teras, Lauren R, Purdue, Mark P, Vajdic, Claire M, Vermeulen, Roel C H, and Giles, Graham G
Published: 2020
Full Text: View/download PDF

204. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma

Author: Bernatsky, Sasha, Velásquez García, Héctor A, Spinelli, John, Gaffney, Patrick, Smedby, Karin E, Ramsey-Goldman, Rosalind, Wang, Sophia S., Adami, Hans-Olov, Albanes, Demetrius, Angelucci, Emanuele, Ansell, Stephen M., Asmann, Yan W., Becker, Nikolaus, Benavente, Yolanda, Berndt, Sonja I., Bertrand, Kimberly A., Birmann, Brenda M., Boeing, Heiner, Boffetta, Paolo, Bracci, Paige M., Brennan, Paul, Brooks-Wilson, Angela R., Cerhan, James R., Chanock, Stephen J., Clavel, Jacqueline, Conde, Lucia, Cotenbader, Karen H, Cox, David G, Cozen, Wendy, Crouch, Simon, De Roos, Anneclaire J., De Sanjose, Silvia, Di Lollo, Simonetta, Diver, W. Ryan, Dogan, Ahmet, Foretova, Lenka, Ghesquières, Hervé, Giles, Graham G., Glimelius, Bengt, Habermann, Thomas M., Haioun, Corinne, Hartge, Patricia, Hjalgrim, Henrik, Holford, Theodore R., Holly, Elizabeth A., Jackson, Rebecca D., Kaaks, Rudolph, Kane, Eleanor, Kelly, Rachel S., Klein, Robert J., Kraft, Peter, Kricker, Anne, Lan, Qing, Lawrence, Charles, Liebow, Mark, Lightfoot, Tracy, Link, Brian K., Maynadie, Marc, McKay, James, Melbye, Mads, Molina, Thierry Jo, Monnereau, Alain, Morton, Lindsay M., Nieters, Alexandra, North, Kari E., Novak, Anne J., Offit, Kenneth, Purdue, Mark P., Rais, Marco, Riby, Jacques, Roman, Eve, Rothman, Nathaniel, Salles, Gilles, Severi, Gianluca, Severson, Richard K., Skibola, Christine F., Slager, Susan L., Smith, Alex, Smith, Martyn T., Southey, Melissa C., Staines, Anthony, Teras, Lauren R., Thompson, Carrie A., Tilly, Hervé, Tinker, Lesley F., Tjonneland, Anne, Turner, Jenny, Vajdic, Claire M., Vermeulen, Roel C H, Vijai, Joseph, Vineis, Paolo, Virtamo, Jarmo, Wang, Zhaoming, Weinstein, Stephanie, Witzig, Thomas E., Zelenetz, Andrew, Zeleniuch-Jacquotte, Anne, Zhang, Yawei, Zheng, Tongzhang, Zucca, Mariagrazia, Clarke, Ann E, Bernatsky, Sasha, Velásquez García, Héctor A, Spinelli, John, Gaffney, Patrick, Smedby, Karin E, Ramsey-Goldman, Rosalind, Wang, Sophia S., Adami, Hans-Olov, Albanes, Demetrius, Angelucci, Emanuele, Ansell, Stephen M., Asmann, Yan W., Becker, Nikolaus, Benavente, Yolanda, Berndt, Sonja I., Bertrand, Kimberly A., Birmann, Brenda M., Boeing, Heiner, Boffetta, Paolo, Bracci, Paige M., Brennan, Paul, Brooks-Wilson, Angela R., Cerhan, James R., Chanock, Stephen J., Clavel, Jacqueline, Conde, Lucia, Cotenbader, Karen H, Cox, David G, Cozen, Wendy, Crouch, Simon, De Roos, Anneclaire J., De Sanjose, Silvia, Di Lollo, Simonetta, Diver, W. Ryan, Dogan, Ahmet, Foretova, Lenka, Ghesquières, Hervé, Giles, Graham G., Glimelius, Bengt, Habermann, Thomas M., Haioun, Corinne, Hartge, Patricia, Hjalgrim, Henrik, Holford, Theodore R., Holly, Elizabeth A., Jackson, Rebecca D., Kaaks, Rudolph, Kane, Eleanor, Kelly, Rachel S., Klein, Robert J., Kraft, Peter, Kricker, Anne, Lan, Qing, Lawrence, Charles, Liebow, Mark, Lightfoot, Tracy, Link, Brian K., Maynadie, Marc, McKay, James, Melbye, Mads, Molina, Thierry Jo, Monnereau, Alain, Morton, Lindsay M., Nieters, Alexandra, North, Kari E., Novak, Anne J., Offit, Kenneth, Purdue, Mark P., Rais, Marco, Riby, Jacques, Roman, Eve, Rothman, Nathaniel, Salles, Gilles, Severi, Gianluca, Severson, Richard K., Skibola, Christine F., Slager, Susan L., Smith, Alex, Smith, Martyn T., Southey, Melissa C., Staines, Anthony, Teras, Lauren R., Thompson, Carrie A., Tilly, Hervé, Tinker, Lesley F., Tjonneland, Anne, Turner, Jenny, Vajdic, Claire M., Vermeulen, Roel C H, Vijai, Joseph, Vineis, Paolo, Virtamo, Jarmo, Wang, Zhaoming, Weinstein, Stephanie, Witzig, Thomas E., Zelenetz, Andrew, Zeleniuch-Jacquotte, Anne, Zhang, Yawei, Zheng, Tongzhang, Zucca, Mariagrazia, and Clarke, Ann E
Abstract: Objective: Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genome-wide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL.Methods: GWAS data on European Caucasians from the International Lymphoma Epidemiology Consortium (InterLymph) provided a total of 3857 DLBCL cases and 7666 general-population controls. Data were pooled in a random-effects meta-analysis.Results: Among the 28 SLE-related SNPs investigated, the two most convincingly associated with risk of DLBCL included the CD40 SLE risk allele rs4810485 on chromosome 20q13 (OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the HLA SLE risk allele rs1270942 on chromosome 6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36, p=0.0362). Of additional possible interest were rs2205960 and rs12537284. The rs2205960 SNP, related to a cytokine of the tumour necrosis factor superfamily TNFSF4, was associated with an OR per risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the rs12537284 (chromosome 7q32, IRF5 gene) risk allele was 1.08, 95% CI 0.99 to 1.18, p=0.0765.Conclusions: These data suggest several plausible genetic links between DLBCL and SLE.
Published: 2017

205. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma

Author: LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-2, dIRAS RA-I&I RA, Bernatsky, Sasha, Velásquez García, Héctor A, Spinelli, John, Gaffney, Patrick, Smedby, Karin E, Ramsey-Goldman, Rosalind, Wang, Sophia S., Adami, Hans-Olov, Albanes, Demetrius, Angelucci, Emanuele, Ansell, Stephen M., Asmann, Yan W., Becker, Nikolaus, Benavente, Yolanda, Berndt, Sonja I., Bertrand, Kimberly A., Birmann, Brenda M., Boeing, Heiner, Boffetta, Paolo, Bracci, Paige M., Brennan, Paul, Brooks-Wilson, Angela R., Cerhan, James R., Chanock, Stephen J., Clavel, Jacqueline, Conde, Lucia, Cotenbader, Karen H, Cox, David G, Cozen, Wendy, Crouch, Simon, De Roos, Anneclaire J., De Sanjose, Silvia, Di Lollo, Simonetta, Diver, W. Ryan, Dogan, Ahmet, Foretova, Lenka, Ghesquières, Hervé, Giles, Graham G., Glimelius, Bengt, Habermann, Thomas M., Haioun, Corinne, Hartge, Patricia, Hjalgrim, Henrik, Holford, Theodore R., Holly, Elizabeth A., Jackson, Rebecca D., Kaaks, Rudolph, Kane, Eleanor, Kelly, Rachel S., Klein, Robert J., Kraft, Peter, Kricker, Anne, Lan, Qing, Lawrence, Charles, Liebow, Mark, Lightfoot, Tracy, Link, Brian K., Maynadie, Marc, McKay, James, Melbye, Mads, Molina, Thierry Jo, Monnereau, Alain, Morton, Lindsay M., Nieters, Alexandra, North, Kari E., Novak, Anne J., Offit, Kenneth, Purdue, Mark P., Rais, Marco, Riby, Jacques, Roman, Eve, Rothman, Nathaniel, Salles, Gilles, Severi, Gianluca, Severson, Richard K., Skibola, Christine F., Slager, Susan L., Smith, Alex, Smith, Martyn T., Southey, Melissa C., Staines, Anthony, Teras, Lauren R., Thompson, Carrie A., Tilly, Hervé, Tinker, Lesley F., Tjonneland, Anne, Turner, Jenny, Vajdic, Claire M., Vermeulen, Roel C H, Vijai, Joseph, Vineis, Paolo, Virtamo, Jarmo, Wang, Zhaoming, Weinstein, Stephanie, Witzig, Thomas E., Zelenetz, Andrew, Zeleniuch-Jacquotte, Anne, Zhang, Yawei, Zheng, Tongzhang, Zucca, Mariagrazia, Clarke, Ann E, LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-2, dIRAS RA-I&I RA, Bernatsky, Sasha, Velásquez García, Héctor A, Spinelli, John, Gaffney, Patrick, Smedby, Karin E, Ramsey-Goldman, Rosalind, Wang, Sophia S., Adami, Hans-Olov, Albanes, Demetrius, Angelucci, Emanuele, Ansell, Stephen M., Asmann, Yan W., Becker, Nikolaus, Benavente, Yolanda, Berndt, Sonja I., Bertrand, Kimberly A., Birmann, Brenda M., Boeing, Heiner, Boffetta, Paolo, Bracci, Paige M., Brennan, Paul, Brooks-Wilson, Angela R., Cerhan, James R., Chanock, Stephen J., Clavel, Jacqueline, Conde, Lucia, Cotenbader, Karen H, Cox, David G, Cozen, Wendy, Crouch, Simon, De Roos, Anneclaire J., De Sanjose, Silvia, Di Lollo, Simonetta, Diver, W. Ryan, Dogan, Ahmet, Foretova, Lenka, Ghesquières, Hervé, Giles, Graham G., Glimelius, Bengt, Habermann, Thomas M., Haioun, Corinne, Hartge, Patricia, Hjalgrim, Henrik, Holford, Theodore R., Holly, Elizabeth A., Jackson, Rebecca D., Kaaks, Rudolph, Kane, Eleanor, Kelly, Rachel S., Klein, Robert J., Kraft, Peter, Kricker, Anne, Lan, Qing, Lawrence, Charles, Liebow, Mark, Lightfoot, Tracy, Link, Brian K., Maynadie, Marc, McKay, James, Melbye, Mads, Molina, Thierry Jo, Monnereau, Alain, Morton, Lindsay M., Nieters, Alexandra, North, Kari E., Novak, Anne J., Offit, Kenneth, Purdue, Mark P., Rais, Marco, Riby, Jacques, Roman, Eve, Rothman, Nathaniel, Salles, Gilles, Severi, Gianluca, Severson, Richard K., Skibola, Christine F., Slager, Susan L., Smith, Alex, Smith, Martyn T., Southey, Melissa C., Staines, Anthony, Teras, Lauren R., Thompson, Carrie A., Tilly, Hervé, Tinker, Lesley F., Tjonneland, Anne, Turner, Jenny, Vajdic, Claire M., Vermeulen, Roel C H, Vijai, Joseph, Vineis, Paolo, Virtamo, Jarmo, Wang, Zhaoming, Weinstein, Stephanie, Witzig, Thomas E., Zelenetz, Andrew, Zeleniuch-Jacquotte, Anne, Zhang, Yawei, Zheng, Tongzhang, Zucca, Mariagrazia, and Clarke, Ann E
Published: 2017

206. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma

Author: Viaccoz, Aurélien, Ducray, François, Tholance, Yannick, Barcelos, Gleicy Keli, Thomas-Maisonneuve, Laure, Ghesquières, Hervé, Meyronet, David, Quadrio, Isabelle, Cartalat-Carel, Stéphanie, Louis-Tisserand, Guy, Jouanneau, Emmanuel, Guyotat, Jacques, Honnorat, Jérôme, Perret-Liaudet, Armand, Viaccoz, Aurélien, Ducray, François, Tholance, Yannick, Barcelos, Gleicy Keli, Thomas-Maisonneuve, Laure, Ghesquières, Hervé, Meyronet, David, Quadrio, Isabelle, Cartalat-Carel, Stéphanie, Louis-Tisserand, Guy, Jouanneau, Emmanuel, Guyotat, Jacques, Honnorat, Jérôme, and Perret-Liaudet, Armand
Abstract: Background The diagnosis of primary central nervous system lymphoma (PCNSL) can be challenging. PCNSL lesions are frequently located deep within the brain, and performing a cerebral biopsy is not always feasible. The aim of this study was to investigate the diagnostic value of CSF neopterin, a marker of neuroinflammation, in immunocompetent patients with suspected PCNSL. Methods We retrospectively reviewed the characteristics of 124 patients with brain tumor (n = 82) or an inflammatory CNS disorder (n = 42) in whom CSF neopterin levels were assessed. Twenty-eight patients had PCNSL, 54 patients had another type of brain tumor (glioma n = 36, metastasis n = 13, other n = 5), and 13 patients had a pseudotumoral inflammatory brain lesion. Results CSF neopterin levels were significantly higher in the patients with PCNSL than in those with other brain tumors (41.8 vs 5.1 nmol/L, P < .001), those with pseudotumoral inflammatory brain lesions (41.8 vs 4.3 nmol/L, P < .001), and those with nontumefactive inflammatory CNS disorders (41.8 vs 3.8 nmol/L, P < .001). In the 95 patients with space-occupying brain lesions, at a cutoff of 10 nmol/L, the sensitivity of this approach was 96% and the specificity was 93% for the diagnosis of PCNSL. The positive and negative predictive values were 84% and 98%, respectively. Conclusion Assessing CSF neopterin levels in patients with a suspected brain tumor might be helpful for the positive and differential diagnosis of PCNSL. A prospective study is warranted to confirm these results
Published: 2017

207. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Author: Sarkozy, Clémentine, Seymour, John Francis, Ferme, Christophe, Caballero, Dolores, Ghesquieres, Hervé, Leppa, Sirpa, Delarue, Richard, Pedersen, Lars Moller, Mounier, Christiane, Gomes Da Silva, Maria, Chassagne-Clement, Catherine, Maerevoet, Marie, and Salles, Gilles
Published: 2014
Full Text: View/download PDF

208. A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study

Author: Ghesquieres, Herve, Rossi, Cedric, Cherblanc, Fanny, Le Guyader, Sandra, Bijou, Fontanet, Sujobert, Pierre, Fabbro-Peray, Pascale, Fornecker, Luc Mathieu, Bernier, Adeline, Baldi, Isabelle, Bouabdallah, Krimo, Laurent, Camille, Oberic, Lucie, Morineau, Nadine, Salles, Gilles A., Ysebaert, Loic, and Monnereau, Alain
Published: 2019
Full Text: View/download PDF

209. Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT

Author: Chavda, Nikesh Dhiraj, Robinson, Stephen, Boumendil, Ariane, Khvedelidze, Irma, Finel, Hervé, Akhtar, Saad, Rauf, M S, Durakovic, Nadira, Vrhovac, Radovan, Musso, Maurizio, Brice, Pauline, Arat, Mutlu, Blaise, Didier, Collin, Matthew P., Romejko-Jarosinska, Joanna, Stamatoullas, Aspasia, Ozkurt, Zubeyde Nur, Robak, Tadeusz, Wahlin, Björn E, Wilson, Keith, Alma, Eleonora, Pastano, Rocco, Castagna, Luca, Bazarbachi, Ali, Ghesquieres, Hervé, Colita, Andrei, and Montoto, Silvia
Published: 2019
Full Text: View/download PDF

210. Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Author: Maurer, Matthew J., Jakobsen, Lasse H., Schmitz, Norbert, Farooq, Umar, Flowers, Christopher R., Brown, Peter de Nully, Thompson, Carrie A., Frederiksen, Henrik, Cunningham, David, Jørgensen, Judit, Poeschel, Viola, Nowakowski, Grzegorz, Seymour, John F., Merli, Francesco, Haioun, Corinne, Ghesquieres, Herve, Ziepert, Marita, Tilly, Herve, Salles, Gilles, Shi, Qian, El-Galaly, Tarec Christoffer C., and Habermann, Thomas M.
Published: 2019
Full Text: View/download PDF

211. Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Author: Ghesquieres, Herve, Casasnovas, Olivier, Nicolas-Virelizier, Emmanuelle, Gandhi Laurent, Damaj, Delwail, Vincent, Touati, Mohamed, Le Du, Katell, Morschhauser, Franck, Bonnet, Christophe, Waultier-Rascalou, Agathe, Orsini-Piocelle, Frederique, André, Marc, Ben Boutieb, Myriam, Morand, Fabienne, Damotte, Diane, Traverse-Glehen, Alexandra, Quittet, Philippe, and Brice, Pauline
Published: 2019
Full Text: View/download PDF

212. Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study

Author: Ghesquieres, Herve, Drouet, Youenn, Huet, Sarah, Cartron, Guillaume, Delfau, Marie-Helene, Offner, Fritz, Brice, Pauline, Xerri, Luc, Bouabdallah, Reda, and Salles, Gilles A.
Published: 2019
Full Text: View/download PDF

213. Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility

Author: Ghesquieres, Herve, Drouet, Youenn, Zala, Manon, Vineis, Paolo, Salles, Gilles A., Nadel, Bertrand, and Roulland, Sandrine
Published: 2019
Full Text: View/download PDF

214. Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Author: Rubinstein, Paul G., Moore, Page C., Bimali, Milan, Chadburn, Amy, Cesarman, Ethel, Rudek, Michelle, Ratner, Lee, Ambinder, Richard F., Henry, David H., Barta, Stefan K., Ghesquieres, Herve, Coppo, Paul, Delobel, Pierre, Boue, Francois, Galicier, Lionel, Ramos, Juan Carlos, Reid, Erin G., Sharon, Elad, Mounier, Nicolas, Besson, Caroline, and Noy, Ariela
Published: 2019
Full Text: View/download PDF

215. Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Author: Rossi, Cédric, André, Marc, Joubert, Clémentine, Fortpied, Catherine, Brice, Pauline, Deau-Fisher, Bénédicte, Ghesquieres, Herve, Fornecker, Luc Mathieu, Gac, Anne-Claire, Lazarovici, Julien, Stamatoullas, Aspasia, Raemakers, John, Federico, Massimo, Maerevoet, Marie, Bailly, Sarah, Kanoun, Salim, Meignan, Michel, Cottereau, Anne Ségolène, and Casasnovas, Rene-Olivier
Published: 2019
Full Text: View/download PDF

216. Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

Author: Manson, Guillaume, Brice, Pauline, Herbaux, Charles, Silva, Maria, Bouabdallah, Krimo, Deau-Fisher, Bénédicte, Bouteloup, Juliette, Schiano de Collela, Jean Marc, Nicolas-Virelizier, Emmanuelle, Maerevoet, Marie, Ghesquieres, Herve, Stamatoulas Bastard, Aspasia, Antier, Chloe, Poizeau, Florence, Dercle, Laurent, and Houot, Roch
Published: 2019
Full Text: View/download PDF

217. PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma – Authors' reply

Author: Casasnovas, René-Olivier, Bouabdallah, Reda, Brice, Pauline, Lazarovici, Julien, Ghesquieres, Hervé, Stamatoullas, Aspasia, Berriolo-Riedinger, Alina, Fornecker, Luc-Matthieu, André, Marc, and Meignan, Michel
Published: 2019
Full Text: View/download PDF

218. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study

Author: Dupuis , Jehan, Morschhauser , Franck, Ghesquières , Hervé, Tilly , Hervé, Casasnovas , Olivier, Thieblemont , Catherine, Ribrag , Vincent, Bossard , Céline, Bras , Fabien Le, Bachy , Emmanuel, Hivert , Bénédicte, Nicolas-Virelizier , Emmanuelle, Jardin , Fabrice, Bastie , Jean-Noel, Amorim , Sandy, Lazarovici , Julien, Martin , Antoine, Coiffier , Bertrand, Le Bras , Fabien, Institut de Mathématiques de Toulouse UMR5219 ( IMT ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National des Sciences Appliquées - Toulouse ( INSA Toulouse ), Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -PRES Université de Toulouse-Université Paul Sabatier - Toulouse 3 ( UPS ) -Université Toulouse - Jean Jaurès ( UT2J ) -Université Toulouse 1 Capitole ( UT1 ), Service d'hématologie, Hôpital Claude Huriez-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Département d'hématologie [Gustave Roussy], Institut Gustave Roussy ( IGR ), Centre Européen de Réalité Virtuelle ( CERV ), École Nationale d'Ingénieurs de Brest ( ENIB ), Centre International de Recherche en Infectiologie ( CIRI ), École normale supérieure - Lyon ( ENS Lyon ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de recherche en neurobiologie - neurophysiologie de Marseille ( CRN2M ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer ( LabEx LipSTIC ), Institut National de la Recherche Agronomique ( INRA ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Université Paris-Sud - Paris 11 ( UP11 ) -École pratique des hautes études ( EPHE ) -Institut Gustave Roussy ( IGR ) -Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Université de Bourgogne ( UB ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Fédération Francophone de la Cancérologie Digestive, FFCD-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université de Franche-Comté ( UFC ), Laboratoire de Parasitologie-Mycologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Diderot - Paris 7 ( UPD7 ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), CHU Henri Mondor, Institut de Mathématiques de Toulouse UMR5219 (IMT), Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-PRES Université de Toulouse-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Hôpital Claude Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Gustave Roussy (IGR), Centre Européen de Réalité Virtuelle (CERV), École Nationale d'Ingénieurs de Brest (ENIB), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en neurobiologie - neurophysiologie de Marseille (CRN2M), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École pratique des hautes études (EPHE)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Diderot - Paris 7 (UPD7), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), and Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)
Subjects: [SDV.CAN]Life Sciences [q-bio]/Cancer, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract: International audience; Romidepsin is a histone deacetylase inhibitor approved in the USA for patients with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting with mainly haematological and gastrointestinal toxicity. Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. We aimed to assess the safety, tolerability, and activity of romidepsin combined with CHOP in patients with previously untreated disease.; We enrolled patients aged 18-80 years with histologically proven, previously untreated, peripheral T-cell lymphoma (Eastern Cooperative Oncology Group performance status ≤2) into a dose-escalation (phase 1b) and expansion (phase 2) study at nine Lymphoma Study Association centres in France. In the dose-escalation phase, we allocated consecutive blocks of three participants to receive eight 3 week cycles of CHOP (intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), and vincristine 1.4 mg/m(2) [maximum 2 mg] on day 1 and oral prednisone 40 mg/m(2) on days 1-5) in association with varying doses of romidepsin. The starting dose was 10 mg/m(2) intravenously on days 1 and 8 of each cycle, and we used a 3 + 3 design. We assessed dose-limiting toxicities only during the first two cycles. The primary endpoint was to determine the recommended dose for the combination. For the phase 2 study, we aimed to increase the cohort of patients receiving the recommended dose to a total of 25 patients. Patients were assessed for safety outcomes at least twice per cycle according to the Common Terminology Criteria for Adverse Events, version 4.0. Safety analyses included all patients who received at least one dose of romidepsin and CHOP. This trial is registered at the European Clinical Trials Database (EudraCT), number 2010-020962-91 and ClinicalTrials.gov, number NCT01280526.; Between Jan 13, 2011, and May 21, 2013, we enrolled 37 patients (18 treated in phase 1b and 19 patients in phase 2). Three of six patients initially treated at 10 mg/m(2) had a dose-limiting toxicity. The dose-escalation committee decided to modify the study protocol to redefine dose-limiting toxicities with regard to haematological toxicity. Three patients were treated with 8 mg/m(2) of romidepsin, an additional three at 10 mg/m(2) (one dose-limiting toxicity), and six patients at 12 mg/m(2) (three dose-limiting toxicities). We chose romidepsin 12 mg/m(2) as the recommended dose for phase 2. Of the 37 patients treated, three had early cardiac events (two myocardial infarctions and one acute cardiac failure). No deaths were attributable to toxicity. 25 (68%) of 37 patients had at least one serious adverse event. Overall, the most frequent serious adverse events were febrile neutropenia (five [14%] of 37 patients), physical health deterioration (five [14%]), lung infection (four [11%]), and vomiting (three [8%]). 33 (89%) of patients had grade 3-4 neutropenia, and 29 (78%) had grade 3-4 thrombocytopenia.; Romidepsin can be combined with CHOP but this combination should now be tested in comparison to CHOP alone in a randomised trial.; Celgene.
Published: 2015

219. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network

Author: Damaj, Gandhi, Ivanoff, Sarah, Coso, Diane, Ysaebert, Loïc, Choquet, Sylvain, Houillier, Caroline, Parcelier, Anne, Abarah, Wajed, Marjanovic, Zora, Gressin, Rémy, Garidi, Reda, Diouf, Momar, Gac, C., Dupuis, Jehan, Troussard, Xavier, Morschhauseur, Franck, Ghesquieres, H., Soussain, Carole, Gac, Anne-Claire, Ghesquières, Hervé, CHU Caen, Normandie Université (NU), CEntre de REcherches en MAthématiques de la DEcision (CEREMADE), Université Paris-Dauphine-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie Clinique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC), Service de neurologie 2 [CHU Pitié-Salpêtrière], CHU Amiens-Picardie, Centre Hospitalier de Meaux, Laboratoire d'Hématologie et d'Immunologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Quentin, Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD), Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Institut de Mathématiques de Toulouse UMR5219 (IMT), Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-PRES Université de Toulouse-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'hématologie biologique [Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CRLCC René Huguenin, and Institut de l'Elevage
Subjects: Adult, Male, Oncology, medicine.medical_specialty, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease-Free Survival, Central Nervous System Neoplasms, Autologous stem-cell transplantation, International Prognostic Index, Internal medicine, Humans, Medicine, Anthracyclines, Progression-free survival, Autografts, education, Survival rate, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Lymphoma, Non-Hodgkin, Induction chemotherapy, Consolidation Chemotherapy, Articles, Hematology, Middle Aged, medicine.disease, Anesthetics, Combined, Lymphoma, Surgery, Survival Rate, Methotrexate, Female, business, Follow-Up Studies, Stem Cell Transplantation
Abstract: International audience; The purpose of our study is to determine the outcome of patients with systemic non-Hodgkin lymphoma presenting with neurologic localization at diagnosis, as well as the impact of consolidation in terms of high-dose therapy followed by autologous stem cell transplantation. Newly diagnosed non-Hodgkin lymphoma patients with concomitant systemic and neurological involvement at diagnosis were included in this study. Sixty patients (37 males; 25 females) were included. Median age was 61 years (23-85 years). Histological subtype was mainly diffuse large B-cell lymphoma (n = 54; 90%). The International prognostic index was over 2 in 41 (72%) patients. Median number of extranodal sites was 2 (range: 1-5). Central nervous system involvement alone was documented in 48 patients. Paravertebral involvement with epidural mass and cord compression and positive cerebrospinal fluid were present in 7 patients. Five patients had both central nervous system and epidural involvement. First-line chemotherapy was mainly anthracycline-based (88%) plus high-dose methotrexate (74%) with or without cytarabine. Consolidation with high-dose therapy followed by autologous stem cell transplantation was performed in 19 patients. For the whole population, overall response rate after induction chemotherapy was 76%. Three-year progression-free survival and overall survival were 42 ± 7% and 44 ± 7%, respectively. For patients under 66 years of age, consolidation strategy using high-dose therapy followed by autologous stem cell transplantation positively impacted 3-year overall survival and progression free survival (P = 0.008) and (P = 0.003), respectively. In multivariate analysis, high-dose therapy had a positive impact on 3-year overall survival and progression-free survival for the whole population as well as for patients under 66 years old in CR after induction therapy (OS [HR=0.22 (0.07-0.67)] and progression-free survival [HR = 0.17 (0.05-0.54)]). In conclusion, non-Hodgkin lymphoma prognosis with concomitant systemic and neurological involvement at diagnosis is poor with a high risk of relapse when treated with conventional chemotherapies alone. This retrospective study supports the feasibility and the potential benefit of a consolidative strategy with high-dose therapy followed by autologous stem cell transplantation in this subset of patients. This strategy and the best intensive chemotherapy regimen remain to be validated in prospective trials.
Published: 2015

220. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

Author: LS IRAS EEPI GRA (Gezh.risico-analyse), Sub Atmospheric physics and chemistry, dIRAS RA-I&I RA, dIRAS RA-2, Machiela, Mitchell J, Lan, Qing, Slager, Susan L, Vermeulen, Roel C H, Teras, Lauren R, Camp, Nicola J, Cerhan, James R, Spinelli, John J, Wang, Sophia S, Nieters, Alexandra, Vijai, Joseph, Yeager, Meredith, Wang, Zhaoming, Ghesquières, Hervé, McKay, James, Conde, Lucia, de Bakker, Paul I W, Cox, David G, Burdett, Laurie, Monnereau, Alain, Flowers, Christopher R, De Roos, Anneclaire J, Brooks-Wilson, Angela R, Giles, Graham G, Melbye, Mads, Gu, Jian, Jackson, Rebecca D, Kane, Eleanor, Purdue, Mark P, Vajdic, Claire M, Albanes, Demetrius, Kelly, Rachel S, Zucca, Mariagrazia, Bertrand, Kimberly A, Zeleniuch-Jacquotte, Anne, Lawrence, Charles, Hutchinson, Amy, Zhi, Degui, Habermann, Thomas M, Link, Brian K, Novak, Anne J, Dogan, Ahmet, Asmann, Yan W, Liebow, Mark, Thompson, Carrie A, Ansell, Stephen M, Witzig, Thomas E, Tilly, Hervé, Haioun, Corinne, Molina, Thierry J, Hjalgrim, Henrik, Glimelius, Bengt, Adami, Hans-Olov, Roos, Göran, Bracci, Paige M, Riby, Jacques, Smith, Martyn T, Holly, Elizabeth A, Cozen, Wendy, Hartge, Patricia, Morton, Lindsay M, Severson, Richard K, Tinker, Lesley F, North, Kari E, Becker, Nikolaus, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, Lightfoot, Tracy, Crouch, Simon, Smith, Alex, Roman, Eve, Diver, W Ryan, Offit, Kenneth, Zelenetz, Andrew, Klein, Robert J, Villano, Danylo J, Zheng, Tongzhang, Zhang, Yawei, Holford, Theodore R, Turner, Jenny, Southey, Melissa C, Clavel, Jacqueline, Virtamo, Jarmo, Weinstein, Stephanie, Riboli, Elio, Vineis, Paolo, Kaaks, Rudolph, Boeing, Heiner, Tjønneland, Anne, Angelucci, Emanuele, Di Lollo, Simonetta, Rais, Marco, De Vivo, Immaculata, Giovannucci, Edward, Kraft, Peter, Huang, Jinyan, Ma, Baoshan, Ye, Yuanqing, Chiu, Brian C H, Liang, Liming, Park, Ju-Hyun, Chung, Charles C, Weisenburger, Dennis D, Fraumeni, Joseph F, Salles, Gilles, Glenn, Martha, Cannon-Albright, Lisa, Curtin, Karen, Wu, Xifeng, Smedby, Karin E, de Sanjose, Silvia, Skibola, Christine F, Berndt, Sonja I, Birmann, Brenda M, Chanock, Stephen J, Rothman, Nathaniel, LS IRAS EEPI GRA (Gezh.risico-analyse), Sub Atmospheric physics and chemistry, dIRAS RA-I&I RA, dIRAS RA-2, Machiela, Mitchell J, Lan, Qing, Slager, Susan L, Vermeulen, Roel C H, Teras, Lauren R, Camp, Nicola J, Cerhan, James R, Spinelli, John J, Wang, Sophia S, Nieters, Alexandra, Vijai, Joseph, Yeager, Meredith, Wang, Zhaoming, Ghesquières, Hervé, McKay, James, Conde, Lucia, de Bakker, Paul I W, Cox, David G, Burdett, Laurie, Monnereau, Alain, Flowers, Christopher R, De Roos, Anneclaire J, Brooks-Wilson, Angela R, Giles, Graham G, Melbye, Mads, Gu, Jian, Jackson, Rebecca D, Kane, Eleanor, Purdue, Mark P, Vajdic, Claire M, Albanes, Demetrius, Kelly, Rachel S, Zucca, Mariagrazia, Bertrand, Kimberly A, Zeleniuch-Jacquotte, Anne, Lawrence, Charles, Hutchinson, Amy, Zhi, Degui, Habermann, Thomas M, Link, Brian K, Novak, Anne J, Dogan, Ahmet, Asmann, Yan W, Liebow, Mark, Thompson, Carrie A, Ansell, Stephen M, Witzig, Thomas E, Tilly, Hervé, Haioun, Corinne, Molina, Thierry J, Hjalgrim, Henrik, Glimelius, Bengt, Adami, Hans-Olov, Roos, Göran, Bracci, Paige M, Riby, Jacques, Smith, Martyn T, Holly, Elizabeth A, Cozen, Wendy, Hartge, Patricia, Morton, Lindsay M, Severson, Richard K, Tinker, Lesley F, North, Kari E, Becker, Nikolaus, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, Lightfoot, Tracy, Crouch, Simon, Smith, Alex, Roman, Eve, Diver, W Ryan, Offit, Kenneth, Zelenetz, Andrew, Klein, Robert J, Villano, Danylo J, Zheng, Tongzhang, Zhang, Yawei, Holford, Theodore R, Turner, Jenny, Southey, Melissa C, Clavel, Jacqueline, Virtamo, Jarmo, Weinstein, Stephanie, Riboli, Elio, Vineis, Paolo, Kaaks, Rudolph, Boeing, Heiner, Tjønneland, Anne, Angelucci, Emanuele, Di Lollo, Simonetta, Rais, Marco, De Vivo, Immaculata, Giovannucci, Edward, Kraft, Peter, Huang, Jinyan, Ma, Baoshan, Ye, Yuanqing, Chiu, Brian C H, Liang, Liming, Park, Ju-Hyun, Chung, Charles C, Weisenburger, Dennis D, Fraumeni, Joseph F, Salles, Gilles, Glenn, Martha, Cannon-Albright, Lisa, Curtin, Karen, Wu, Xifeng, Smedby, Karin E, de Sanjose, Silvia, Skibola, Christine F, Berndt, Sonja I, Birmann, Brenda M, Chanock, Stephen J, and Rothman, Nathaniel
Published: 2016

221. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

Author: Sarkozy, Clémentine, primary, Molina, Thierry, additional, Ghesquières, Hervé, additional, Michallet, Anne-Sophie, additional, Dupuis, Jehan, additional, Damotte, Diane, additional, Morsschauser, Franck, additional, Parrens, Marie, additional, Martin, Laurent, additional, Dartigues, Peggy, additional, Stamatoullas, Aspasia, additional, Hirsch, Pierre, additional, Fabiani, Bettina, additional, Bouabdallah, Krimo, additional, da Silva, Maria Gomes, additional, Maerevoet, Marie, additional, Laurent, Camille, additional, Coiffier, Bertrand, additional, Salles, Gilles, additional, and Traverse-Glehen, Alexandra, additional
Published: 2016
Full Text: View/download PDF

222. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts

Author: Ghesquières, Hervé, primary, Larrabee, Beth R., additional, Casasnovas, Olivier, additional, Maurer, Matthew J., additional, McKay, James D., additional, Ansell, Stephen M., additional, Montgomery, Dorothy, additional, Asmann, Yan W., additional, Farrell, Katrina, additional, Verney, Aurélie, additional, Slager, Susan L., additional, Allmer, Cristine, additional, Perrot, Aurore, additional, Delarue, Richard, additional, Habermann, Thomas M., additional, Dupuis, Jehan, additional, Link, Brian K., additional, Canioni, Danielle, additional, Dogan, Ahmet, additional, Cozen, Wendy, additional, Jarrett, Ruth F., additional, Cerhan, James R., additional, and Salles, Gilles, additional
Published: 2016
Full Text: View/download PDF

223. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

Author: Maurer, Matthew J., primary, Bachy, Emmanuel, additional, Ghesquières, Hervé, additional, Ansell, Stephen M., additional, Nowakowski, Grzegorz S., additional, Thompson, Carrie A., additional, Inwards, David J., additional, Allmer, Cristine, additional, Chassagne-Clément, Catherine, additional, Nicolas-Virelizier, Emmanuelle, additional, Sebban, Catherine, additional, Lebras, Laure, additional, Sarkozy, Clementine, additional, Macon, William R., additional, Feldman, Andrew L., additional, Syrbu, Sergei I., additional, Traverse-Glehan, Alexandra, additional, Coiffier, Bertrand, additional, Slager, Susan L., additional, Weiner, George J., additional, Witzig, Thomas E., additional, Habermann, Thomas M., additional, Salles, Gilles, additional, Cerhan, James R., additional, and Link, Brian K., additional
Published: 2016
Full Text: View/download PDF

224. FCGR3A /2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts

Author: Ghesquières, Hervé, primary, Larrabee, Beth R., additional, Haioun, Corinne, additional, Link, Brian K., additional, Verney, Aurélie, additional, Slager, Susan L., additional, Ketterer, Nicolas, additional, Ansell, Stephen M., additional, Delarue, Richard, additional, Maurer, Matthew J., additional, Fitoussi, Olivier, additional, Habermann, Thomas M., additional, Peyrade, Fréderic, additional, Dogan, Ahmet, additional, Molina, Thierry J., additional, Novak, Anne J., additional, Tilly, Hervé, additional, Cerhan, James R., additional, and Salles, Gilles, additional
Published: 2016
Full Text: View/download PDF

225. Ventriculitis revealing Bing-Neel syndrome in a patient without Waldenstrom's macroglobulinemia

Author: Ritzenthaler, Thomas, Leray, Véronique, Bourdin, Gaël, Baudry, Thomas, Domnisoru, Izabela-Irina, Ghesquières, Hervé, Saint Pierre, Ghislaine, Ducray, François, and Guerin, Claude
Published: 2013
Full Text: View/download PDF

226. Poster: ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Author: Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, and Lugtenburg, Pieternella
Published: 2022
Full Text: View/download PDF

227. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

Author: Cerhan, James R., Berndt, Sonja I., Vijai, Joseph, Ghesquières, Hervé, McKay, James, Wang, Sophia S., Wang, Zhaoming, Yeager, Meredith, Conde, Lucia, De Bakker, Paul I W, Nieters, Alexandra, Cox, David, Burdett, Laurie, Monnereau, Alain, Flowers, Christopher R., De Roos, Anneclaire J., Brooks-Wilson, Angela R., Lan, Qing, Severi, Gianluca, Melbye, Mads, Gu, Jian, Jackson, Rebecca D., Kane, Eleanor, Teras, Lauren R., Purdue, Mark P., Vajdic, Claire M., Spinelli, John J., Giles, Graham G., Albanes, Demetrius, Kelly, Rachel S., Zucca, Mariagrazia, Bertrand, Kimberly A., Zeleniuch-Jacquotte, Anne, Lawrence, Charles, Hutchinson, Amy, Zhi, Degui, Habermann, Thomas M., Link, Brian K., Novak, Anne J., Dogan, Ahmet, Asmann, Yan W., Liebow, Mark, Thompson, Carrie A., Ansell, Stephen M., Witzig, Thomas E., Weiner, George J., Veron, Amelie S., Zelenika, Diana, Tilly, Hervé, Haioun, Corinne, Molina, Thierry Jo, Hjalgrim, Henrik, Glimelius, Bengt, Adami, Hans Olov, Bracci, Paige M., Riby, Jacques, Smith, Martyn T., Holly, Elizabeth A., Cozen, Wendy, Hartge, Patricia, Morton, Lindsay M., Severson, Richard K., Tinker, Lesley F., North, Kari E., Becker, Nikolaus, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, Lightfoot, Tracy, Crouch, Simon, Smith, Alex, Roman, Eve, Diver, W. Ryan, Offit, Kenneth, Zelenetz, Andrew, Klein, Robert J., Villano, Danylo J., Zheng, Tongzhang, Zhang, Yawei, Holford, Theodore R., Kricker, Anne, Turner, Jenny, Southey, Melissa C., Clavel, Jacqueline, Virtamo, Jarmo, Weinstein, Stephanie, Riboli, Elio, Vineis, Paolo, Kaaks, Rudolph, Trichopoulos, Dimitrios, Vermeulen, Roel C H, Boeing, Heiner, Tjonneland, Anne, Angelucci, Emanuele, Di Lollo, Simonetta, Rais, Marco, Birmann, Brenda M., Laden, Francine, Giovannucci, Edward, Kraft, Peter, Huang, Jinyan, Ma, Baoshan, Ye, Yuanqing, Chiu, Brian C H, Sampson, Joshua, Liang, Liming, Park, Ju Hyun, Chung, Charles C., Weisenburger, Dennis D., Chatterjee, Nilanjan, Fraumeni, Joseph F., Slager, Susan L., Wu, Xifeng, De Sanjose, Silvia, Smedby, Karin E., Salles, Gilles, Skibola, Christine F., Rothman, Nathaniel, Chanock, Stephen J., LS IRAS EEPI GRA (Gezh.risico-analyse), Risk Assessment of Toxic and Immunomodulatory Agents, and IRAS RATIA-SIB
Abstract: Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of 3 new genome-wide association studies (GWAS) and 1 previous scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of 9 promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (EXOC2; P = 2.33 × 10 '21), rs2523607 at 6p21.33 (HLA-B; P = 2.40 × 10 '10), rs79480871 at 2p23.3 (NCOA1; P = 4.23 × 10 '8) and two independent SNPs, rs13255292 and rs4733601, at 8q24.21 (PVT1; P = 9.98 × 10 '13 and 3.63 × 10 '11, respectively). These data provide substantial new evidence for genetic susceptibility to this B cell malignancy and point to pathways involved in immune recognition and immune function in the pathogenesis of DLBCL.
Published: 2014

228. Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region

Author: Birmann, Brenda M., Berndt, Sonja I., Yeager, Meredith, Salles, Gilles, Kricker, Anne, Morton, Lindsay M., Slager, Susan L., Becker, Nikolaus, Link, Brian K., Hjalgrim, Henrik, Wang, Zhaoming, Vijai, Joseph, de Sanjose, Silvia, Melbye, Mads, Foo, Jia-Nee, Severi, Gianluca, Teras, Lauren R., Bracci, Paige M., Ghesquières, Hervé, Linet, Martha S., Gu, Jian, Tinker, Lesley F., Skibola, Christine F., Wang, Sophia S., Vermeulen, Roel C.H., Lan, Qing, Vajdic, Claire M., Smith, Alex, Lightfoot, Tracy, Conde, Lucia, de Bakker, Paul I.W., and Holly, Elizabeth A.
Abstract: Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants. To identify additional FL susceptibility loci, we conducted a large-scale two-stage GWAS in 4,523 case subjects and 13,344 control subjects of European ancestry. Five non-HLA loci were associated with FL risk: 11q23.3 (rs4938573, p = 5.79 × 10−20) near CXCR5; 11q24.3 (rs4937362, p = 6.76 × 10−11) near ETS1; 3q28 (rs6444305, p = 1.10 × 10−10) in LPP; 18q21.33 (rs17749561, p = 8.28 × 10−10) near BCL2; and 8q24.21 (rs13254990, p = 1.06 × 10−8) near PVT1. In an analysis of the HLA region, we identified four linked HLA-DRβ1 multiallelic amino acids at positions 11, 13, 28, and 30 that were associated with FL risk (pomnibus = 4.20 × 10−67 to 2.67 × 10−70). Additional independent signals included rs17203612 in HLA class II (odds ratio [ORper-allele] = 1.44; p = 4.59 × 10−16) and rs3130437 in HLA class I (ORper-allele = 1.23; p = 8.23 × 10−9). Our findings further expand the number of loci associated with FL and provide evidence that multiple common variants outside the HLA region make a significant contribution to FL risk.
Published: 2014
Full Text: View/download PDF

229. Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Author: Aussedat, Guillaume, Maucort-Boulch, Delphine, Rey, Philippe, Safar, Violaine, Karlin, Lionel, Elsensohn, Mad-Helenie, Lebras, Laure, Sarkozy, Clementine, Bachy, Emmanuel, Favier, Bertrand, Vantard, Nicolas, Sesques, Pierre, Lazareth, Anne, Ferrant, Emmanuelle, Ghergus, Dana, Salles, Gilles, Nicolas-Virelizier, Emmanuelle, and Ghesquieres, Herve
Published: 2018
Full Text: View/download PDF

230. A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers

Author: Golfier, Camille, Maucort-Boulch, Delphine, Nicolas-Virelizier, Emmanuelle, Rossi, Cedric, Sesques, Pierre, Vantard, Nicolas, Favier, Bertrand, Bachy, Emmanuel, Broussais-Guillaumot, Florence, Ferrant, Emmanuelle, Ghergus, Dana, Karlin, Lionel, Lazareth, Anne, Safar, Violaine, Sarkozy, Clementine, Assaad, Souad, Lebras, Laure, Rey, Philippe, Bastie, Jean-Noel, Traverse-Glehen, Alexandra, Martin, Laurent, Tordo, Jeremie, Berriolo-Riedinger, Alina, Salles, Gilles, Casasnovas, Rene-Olivier, and Ghesquieres, Herve
Published: 2018
Full Text: View/download PDF

231. Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma

Author: Perrier, Lionel, Lefranc, Anne, Quittet, Philippe, Moreau, Philippe, Siani, Carole, Ghesquières, Hervé, Jardin, Fabrice, Favier, Bertrand, Ifrah, Norbert, Lissandre, Séverine, Pérol, David, Sebban, Catherine, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], Service d'hématologie et oncologie médicale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Hématologie et oncologie pédiatrique, Entrepôts, Représentation et Ingénierie des Connaissances (ERIC), Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Département Hématologie (FNCLCC), Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Department of Pharmacy, Service d'hématologie clinique [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Department of Biostatistics, Department of Medical Oncology, Dao, Taï, Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP]
Subjects: JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets, Filgrastim, JEL: I - Health, Education, and Welfare/I.I1 - Health, Cost-effectiveness, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, ComputingMilieux_MISCELLANEOUS, Pegfilgrastim, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I18 - Government Policy • Regulation • Public Health
Abstract: International audience
Published: 2013
Full Text: View/download PDF

232. Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial

Author: Mounier, Nicolas, Heutte, Natacha, Thieblemont, Catherine, Briere, Josette, Gaulard, Philippe, Feugier, Pierre, Ghesquieres, Hervé, Van Den Neste, Eric, Robu, Daniela, Tilly, Herve, Bouabdallah, Reda, Safar, Violaine, and Coiffier, Bertrand
Published: 2012
Full Text: View/download PDF

233. Isavuconazole off-label use as an empirical treatment of invasive fungal infections

Author: Bienvenu, Anne-Lise, Gasser, Chloe, Ducastelle-Lepretre, Sophie, Bleyzac, Nathalie, Piriou, Vincent, Durieu, Isabelle, Roux, Sandrine, Millet, Aurélien, Ghesquières, Hervé, Leboucher, Gilles, and Goutelle, Sylvain
Abstract: •Isavuconazole off-labelled use as an empirical therapy.•Prescription review to study this clinical practice.•Good mycological efficacy and hepatic safety of empirical isavuconazole.•Early reevaluation of isavuconazole to maximise the safety profile.•Isavuconazole therapeutic drug monitoring to ensure an optimal exposure.
Published: 2024
Full Text: View/download PDF

234. Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in adult patients with lymphoma and myeloma: cost-effectiveness evaluation alongside a randomized controlled trial

Author: Perrier, Lionel, Lefranc, Anne, Quittet, Philippe, Ghesquières, Hervé, Favier, Bertrand, Espinouse, Daniel, de Peretti, Christian, Moles, Marie Pierre, Cacheux, Victoria, Leprêtre, Stéphane, Renaud, Marc, Pérol, David, Sylvestre-Baron, Patrick, Sebban, Catherine, Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Centre Léon Bérard [Lyon], Service d'hématologie et oncologie médicale, Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Département Hématologie (FNCLCC), Department of Pharmacy, Hématologie clinique, CHU Lyon, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), HEMATOLOGIE, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Département d'Hématologie et Oncologie Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Department of Biostatistics, Department of Medical Oncology, Dao, Taï, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), and Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM)
Subjects: JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets, Filgrastim, JEL: I - Health, Education, and Welfare/I.I1 - Health, Cost-effectiveness, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Pegfilgrastim, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I18 - Government Policy • Regulation • Public Health
Published: 2011

235. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network

Author: Langner-Lemercier, Sophie, primary, Houillier, Caroline, additional, Soussain, Carole, additional, Ghesquières, Hervé, additional, Chinot, Olivier, additional, Taillandier, Luc, additional, Soubeyran, Pierre, additional, Lamy, Thierry, additional, Morschhauser, Franck, additional, Benouaich-Amiel, Alexandra, additional, Ahle, Guido, additional, Moles-Moreau, Marie-Pierre, additional, Moluçon-Chabrot, Cécile, additional, Bourquard, Pascal, additional, Damaj, Ghandi, additional, Jardin, Fabrice, additional, Larrieu, Delphine, additional, Gyan, Emmanuel, additional, Gressin, Remy, additional, Jaccard, Arnaud, additional, Choquet, Sylvain, additional, Brion, Annie, additional, Casasnovas, Olivier, additional, Colin, Philippe, additional, Reman, Oumedaly, additional, Tempescul, Adrian, additional, Marolleau, Jean-Pierre, additional, Fabbro, Michel, additional, Naudet, Florian, additional, Hoang-Xuan, Khê, additional, and Houot, Roch, additional
Published: 2016
Full Text: View/download PDF

236. Étude des polymorphismes génétiques des gènes des cytokines dans les lymphomes hodgkiniens

Author: Ghesquières, Hervé, Laboratoire de Biologie Moléculaire de la Cellule (LBMC), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard - Lyon I, and Gilles Salles
Subjects: [SDV.SA]Life Sciences [q-bio]/Agricultural sciences, Pronostic, SNP, Lymphome Hodgkinien, Prognosis, Cytokine, Hodgkin lymphoma
Abstract: Cytokines are important immune mediators implicated in Hodgkin lymphoma (HL) pathogenesis but little is known on the role of immune gene variations. We assessed prospectively the prognostic role of cytokine gene single nucleotide polymorphisms (SNPs) in HL patients (pts) : IL10 (rs1800890, 448 pts; rs1800896, 459 pts ; rs1800871, 446 pts ; rs1800872, 447 pts), TNFA (rs1800629, 464 pts) ; IL6 (rs1800795, 201 pts) ; IL1B (rs16944, 198 pts) ; ILRN (rs419598, 199 pts) ; INFG (rs2430561, 200 pts) ; IL12 (rs3212227, 259 pts) ; CCL17 (rs223828, 198 pts). IL12 genotype distribution appears significantly different from what observed in general population according to Hardy-Weinberg test which was already observed in another published study. IL10-1082AA genotype was associated with better complete response than other IL10 genotypes (95% vs. 88% P = .02). For patients with stage III-IV HL, the 6-year overall survival was statistically different between IL10-592AA/CC/AC and IL10-819TT/CC/CT genotypes (100%, 94%, 78%, P = .03). This prognostic effect was observed in EBV-negative but not in EBV-positive HL. In EBV-negative HL, TNFA-308AA/GG/AG genotypes had a different 6-year progression-free survival (100%, 84%, 68%, P = .03). No correlation was observed between genotypes and IL-10, TNFA, IL-1RA, IL-6 cytokine levels. This exploratory study suggests an effect of IL10 and TNFA SNPs in predicting HL outcome but other studies are needed to decipher the role of the host immunogenetic background, in particular the relation with EBV. Regarding the IL12 genotyping results, whether IL12 polymorphism is implicated in HL susceptibility needs also to be clarify.; Les cytokines sont d’importants médiateurs dans la physiopathologie des lymphomes hodgkiniens (LH). A partir d’une cohorte de 464 patients, nous avons évalué l’impact pronostique de onze SNPs parmi les gènes de cytokines : IL10 (rs1800890, rs1800896, rs1800871, rs1800872), TNFA (rs1800629) ; IL6 (rs1800795) ; IL1B (rs16944) ; ILRN (rs419598) ; INFG (rs2430561) ; IL12 (rs3212227) ; CCL17 (rs223828). Le génotypage du SNP de l’IL12 montre une distribution différente de celle attendue dans la population générale selon le test de Hardy-Weinberg. Ce résultat suggère que les variations génétiques de l’IL12 pourraient être impliquées dans la susceptibilité au LH. Les patients porteurs du génotype IL10-1082AA présentent un taux de rémission complète au traitement initial supérieur aux patients présentant un autre génotype (95% vs. 88% P = .02). Pour les patients de stade avancé III-IV, le taux de survie globale à 6 ans est statistiquement différent entre les génotypes IL10-592AA/CC/AC et IL10-819TT/CC/CT (100%, 94%, 78%, P = .03). Ce résultat est retrouvé pour les patients porteurs de LH n’exprimant pas l’EBV. Pour les LH EBV négatif, le taux de survie sans progression à 6 ans est différent en fonction du génotype du TNFA-308AA/GG/AG (100%, 84%, 68%, P = .03). Il n’a été pas retrouvé de corrélation entre les génotypes et les dosages plasmatiques de l’IL-10, TNFA, IL-1RA, IL-6. Cette étude montre que le ‘‘fond génétique immun’’ est important à prendre en considération pour définir le pronostic des patients. Le rôle des SNPs de l’IL10 et du TNFA dans les LH EBV négatif devra être confirmé ainsi que l’influence des variations génétiques de l’IL12 dans la susceptibilité au LH.
Published: 2010

237. Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC

Author: Herbaux, Charles, primary, Gauthier, Jordan, additional, Brice, Pauline, additional, Fornecker, Luc, additional, Bouabdallah, Krimo, additional, Manson, Guillaume, additional, Ghesquières, Hervé, additional, Thiebaut-Bertrand, Anne, additional, Demarquette, Hélène, additional, Boyle, Eileen, additional, Ysebaert, Loic, additional, Houot, Roch, additional, Yakoub-Agha, Ibrahim, additional, and Morschhauser, Franck, additional
Published: 2015
Full Text: View/download PDF

238. Impact of 18 f-Fluoro-Deoxyglucose Positron Emission Tomography Imaging in the Management of Mantle Cell Lymphoma

Author: Bouteloup, Juliette, primary, Kanoun, Salim, additional, Berriolo-Riedinger, Alina, additional, Ghesquières, Hervé, additional, Salles, Gilles A., additional, Gargi, Thérèse, additional, Mognetti, Thomas, additional, Nicolas-Virelizier, Emmanuelle, additional, Belhabri, Amine, additional, Philippe, Rey, additional, Voillat, Laurent, additional, Rossi, Cedric, additional, Noël, Robin, additional, Bastie, Jean-Noel M., additional, and Casasnovas, Olivier, additional
Published: 2015
Full Text: View/download PDF

239. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma

Author: Viaccoz, Aurélien, primary, Ducray, François, additional, Tholance, Yannick, additional, Barcelos, Gleicy Keli, additional, Thomas-Maisonneuve, Laure, additional, Ghesquières, Hervé, additional, Meyronet, David, additional, Quadrio, Isabelle, additional, Cartalat-Carel, Stéphanie, additional, Louis-Tisserand, Guy, additional, Jouanneau, Emmanuel, additional, Guyotat, Jacques, additional, Honnorat, Jérôme, additional, and Perret-Liaudet, Armand, additional
Published: 2015
Full Text: View/download PDF

240. Study of germline single nucleotide polymorphisms in cytokine genes of patients with Hodgkin Lymphoma

Author: Ghesquières, Hervé and STAR, ABES
Subjects: [SDV.SA] Life Sciences [q-bio]/Agricultural sciences, Pronostic, SNP, Lymphome Hodgkinien, Prognosis, Cytokine, Hodgkin lymphoma
Abstract: Cytokines are important immune mediators implicated in Hodgkin lymphoma (HL) pathogenesis but little is known on the role of immune gene variations. We assessed prospectively the prognostic role of cytokine gene single nucleotide polymorphisms (SNPs) in HL patients (pts) : IL10 (rs1800890, 448 pts; rs1800896, 459 pts ; rs1800871, 446 pts ; rs1800872, 447 pts), TNFA (rs1800629, 464 pts) ; IL6 (rs1800795, 201 pts) ; IL1B (rs16944, 198 pts) ; ILRN (rs419598, 199 pts) ; INFG (rs2430561, 200 pts) ; IL12 (rs3212227, 259 pts) ; CCL17 (rs223828, 198 pts). IL12 genotype distribution appears significantly different from what observed in general population according to Hardy-Weinberg test which was already observed in another published study. IL10-1082AA genotype was associated with better complete response than other IL10 genotypes (95% vs. 88% P = .02). For patients with stage III-IV HL, the 6-year overall survival was statistically different between IL10-592AA/CC/AC and IL10-819TT/CC/CT genotypes (100%, 94%, 78%, P = .03). This prognostic effect was observed in EBV-negative but not in EBV-positive HL. In EBV-negative HL, TNFA-308AA/GG/AG genotypes had a different 6-year progression-free survival (100%, 84%, 68%, P = .03). No correlation was observed between genotypes and IL-10, TNFA, IL-1RA, IL-6 cytokine levels. This exploratory study suggests an effect of IL10 and TNFA SNPs in predicting HL outcome but other studies are needed to decipher the role of the host immunogenetic background, in particular the relation with EBV. Regarding the IL12 genotyping results, whether IL12 polymorphism is implicated in HL susceptibility needs also to be clarify., Les cytokines sont d’importants médiateurs dans la physiopathologie des lymphomes hodgkiniens (LH). A partir d’une cohorte de 464 patients, nous avons évalué l’impact pronostique de onze SNPs parmi les gènes de cytokines : IL10 (rs1800890, rs1800896, rs1800871, rs1800872), TNFA (rs1800629) ; IL6 (rs1800795) ; IL1B (rs16944) ; ILRN (rs419598) ; INFG (rs2430561) ; IL12 (rs3212227) ; CCL17 (rs223828). Le génotypage du SNP de l’IL12 montre une distribution différente de celle attendue dans la population générale selon le test de Hardy-Weinberg. Ce résultat suggère que les variations génétiques de l’IL12 pourraient être impliquées dans la susceptibilité au LH. Les patients porteurs du génotype IL10-1082AA présentent un taux de rémission complète au traitement initial supérieur aux patients présentant un autre génotype (95% vs. 88% P = .02). Pour les patients de stade avancé III-IV, le taux de survie globale à 6 ans est statistiquement différent entre les génotypes IL10-592AA/CC/AC et IL10-819TT/CC/CT (100%, 94%, 78%, P = .03). Ce résultat est retrouvé pour les patients porteurs de LH n’exprimant pas l’EBV. Pour les LH EBV négatif, le taux de survie sans progression à 6 ans est différent en fonction du génotype du TNFA-308AA/GG/AG (100%, 84%, 68%, P = .03). Il n’a été pas retrouvé de corrélation entre les génotypes et les dosages plasmatiques de l’IL-10, TNFA, IL-1RA, IL-6. Cette étude montre que le ‘‘fond génétique immun’’ est important à prendre en considération pour définir le pronostic des patients. Le rôle des SNPs de l’IL10 et du TNFA dans les LH EBV négatif devra être confirmé ainsi que l’influence des variations génétiques de l’IL12 dans la susceptibilité au LH.
Published: 2010

241. Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

Author: Aussedat, Guillaume, Ghesquières, Hervé, Stamatoullas, Aspasia, Hirsch, Pierre, Nicolas-Virelizier, Emmanuelle, Cartron, Guillaume, Regny, Caroline, Karlin, Lionel, Chassagne-Clément, Catherine, Safar, Violaine, Albin, Nicolas, Deleuze, Antoine, Lambour, Alexis, Daguindau, Nicolas, Copie, Christiane, Lemal, Richard, Salles, Gilles, traverse-Glehen, Alexandra, and Sarkozy, Clementine
Published: 2017
Full Text: View/download PDF

242. Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Author: Maurer, Matthew J, Ghesquières, Hervé, Link, Brian K, Jais, Jean-Philippe, Habermann, Thomas M, Thompson, Carrie A, Haioun, Corinne, Allmer, Cristine, Johnston, Patrick B, Delarue, Richard, Micallef, Ivana N, Peyrade, Frederic, Inwards, David J, Ketterer, Nicolas, Farooq, Umar, Fitoussi, Olivier, Macon, William R, Molina, Thierry Jo, Syrbu, Sergei, Feldman, Andrew L, Slager, Susan L, Weiner, George J, Ansell, Stephen M, Cerhan, James R., Salles, Gilles Andre, Witzig, Thomas E, Tilly, Herve, and Nowakowski, Grzegorz S
Published: 2017
Full Text: View/download PDF

243. Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Author: Sarkozy, Clementine, Traverse-Glehen, Alexandra, Bachy, Emmanuel, Karlin, Lionel, Ghesquières, Hervé, Besson, Hervé, Hermans, Ruben, Healy, Nollaig, Garside, Jamie, Diels, Joris, MacDougall, Finlay, Pick-Lauer, Corinna, and Salles, Gilles
Published: 2017
Full Text: View/download PDF

244. The impact of CD34+ cell dose on the cost of HDT with PBSC transplantation in lymphomia

Author: Morelle, Magali, Perrier, Lionel, Ghesquières, Hervé, Sebban, Catherine, Philip, Irène, Latour, Jean-François, Biron, Pierre, Groupe d'analyse et de théorie économique (GATE), Université Lumière - Lyon 2 (UL2)-Ecole Normale Supérieure Lettres et Sciences Humaines (ENS LSH)-Centre National de la Recherche Scientifique (CNRS), Groupe de Recherche en Economie de la SAnté et réseaux de soins en Cancérologie (GRESAC), Centre National de la Recherche Scientifique (CNRS), Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), Centre Léon Bérard [Lyon], and Dao, Taï
Subjects: CD34+ cell, lymphomia, impaxt, cost, HDT, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, PBSC, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, ComputingMilieux_MISCELLANEOUS, transplantation
Abstract: National audience
Published: 2007

245. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <italic>MYC</italic>/<italic>PVT1</italic> predicts patient outcome in two independent cohorts.

Author: Ghesquières, Hervé, Larrabee, Beth R., Casasnovas, Olivier, Maurer, Matthew J., McKay, James D., Ansell, Stephen M., Montgomery, Dorothy, Asmann, Yan W., Farrell, Katrina, Verney, Aurélie, Slager, Susan L., Allmer, Cristine, Perrot, Aurore, Delarue, Richard, Habermann, Thomas M., Dupuis, Jehan, Link, Brian K., Canioni, Danielle, Dogan, Ahmet, and Cozen, Wendy
Subjects: *HODGKIN'S disease, *LYMPHOMAS
Published: 2018
Full Text: View/download PDF

246. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.

Author: Akhtar, Saad, Montoto, Silvia, Boumendil, Ariane, Finel, Herve, Masszi, Tamas, Jindra, Pavel, Nemet, Damir, Fuhrmann, Stephan, Beguin, Yves, Castagna, Luca, Ferrara, Felicetto, Capria, Saveria, Malladi, Ram, Moraleda, Jose Maria, Bloor, Adrian, Ghesquières, Hervé, Meissner, Julia, Sureda, Anna, and Dreger, Peter
Published: 2018
Full Text: View/download PDF

247. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.

Author: Houillier, Caroline, Ghesquières, Hervé, Chabrot, Cécile, Soussain, Carole, Ahle, Guido, Choquet, Sylvain, Nicolas-Virelizier, Emmanuelle, Bay, Jacques-Olivier, Vargaftig, Jacques, Gaultier, Claude, Touitou, Valérie, Martin-Duverneuil, Nadine, Cassoux, Nathalie, Garff-Tavernier, Magali, Costopoulos, Myrto, Faurie, Pierre, and Hoang-Xuan, Khê
Abstract: Primary CNS lymphoma (PCNSL) is chemosensitive to high-dose methotrexate-based chemotherapy. However, responses in the elderly are short-lasting and outcome is poor. Given that radiotherapy and intensive chemotherapy expose elderly to severe toxicities, alternative consolidation approaches need to be evaluated. In this multicenter study, we retrospectively analyzed consecutive patients with newly-diagnosed PCNSL, aged >60, treated with a (R)-MPV-AAA regimen. The regimen consisted of three 28-day cycles of methotrexate (3.5 g/m D1, D15), procarbazine, vincristine, followed by three 28-day cycles of cytarabine consolidation (3 g/m D1-2). Addition of rituximab (375 mg/m D1) was optional. The results were compared with the historical MPV-A regimen. Ninety patients received the (R)-MPV-AAA regimen with (n = 39) or without (n = 51) rituximab. Median age was 68 and median KPS 60. 55% of patients achieved a complete response, 8% a partial response and 37% progressed. The median PFS was 10 months, the median OS 28.1 months. Toxicity was mainly hematological, with 54 and 51% of grade III-IV neutropenia and thrombopenia. The response rate was higher in patients receiving rituximab (77 vs. 53%; p = 0.03), whereas no difference was observed in terms of PFS or OS. When comparing the results to the historical MPV-A, there was no difference in terms of response rate, PFS or OS, but a higher rate of hematotoxicity. This study suggests that extending cytarabine consolidation after methotrexate-based chemotherapy does not improve the MPV-A efficacy but increases toxicity in the elderly. The addition of rituximab may improve the response rate, but its impact on final outcome remains unclear. [ABSTRACT FROM AUTHOR]
Published: 2017
Full Text: View/download PDF

248. Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region

Author: Skibola, Christine F, Skibola, Christine F, Berndt, Sonja I, Vijai, Joseph, Conde, Lucia, Wang, Zhaoming, Yeager, Meredith, de Bakker, Paul IW, Birmann, Brenda M, Vajdic, Claire M, Foo, Jia-Nee, Bracci, Paige M, Vermeulen, Roel CH, Slager, Susan L, de Sanjose, Silvia, Wang, Sophia S, Linet, Martha S, Salles, Gilles, Lan, Qing, Severi, Gianluca, Hjalgrim, Henrik, Lightfoot, Tracy, Melbye, Mads, Gu, Jian, Ghesquières, Hervé, Link, Brian K, Morton, Lindsay M, Holly, Elizabeth A, Smith, Alex, Tinker, Lesley F, Teras, Lauren R, Kricker, Anne, Becker, Nikolaus, Purdue, Mark P, Spinelli, John J, Zhang, Yawei, Giles, Graham G, Vineis, Paolo, Monnereau, Alain, Bertrand, Kimberly A, Albanes, Demetrius, Zeleniuch-Jacquotte, Anne, Gabbas, Attilio, Chung, Charles C, Burdett, Laurie, Hutchinson, Amy, Lawrence, Charles, Montalvan, Rebecca, Liang, Liming, Huang, Jinyan, Ma, Baoshan, Liu, Jianjun, Adami, Hans-Olov, Glimelius, Bengt, Ye, Yuanqing, Nowakowski, Grzegorz S, Dogan, Ahmet, Thompson, Carrie A, Habermann, Thomas M, Novak, Anne J, Liebow, Mark, Witzig, Thomas E, Weiner, George J, Schenk, Maryjean, Hartge, Patricia, De Roos, Anneclaire J, Cozen, Wendy, Zhi, Degui, Akers, Nicholas K, Riby, Jacques, Smith, Martyn T, Lacher, Mortimer, Villano, Danylo J, Maria, Ann, Roman, Eve, Kane, Eleanor, Jackson, Rebecca D, North, Kari E, Diver, W Ryan, Turner, Jenny, Armstrong, Bruce K, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, McKay, James, Brooks-Wilson, Angela R, Zheng, Tongzhang, Holford, Theodore R, Chamosa, Saioa, Kaaks, Rudolph, Kelly, Rachel S, Ohlsson, Bodil, Travis, Ruth C, Weiderpass, Elisabete, Clavel, Jacqueline, Giovannucci, Edward, Kraft, Peter, Virtamo, Jarmo, Skibola, Christine F, Skibola, Christine F, Berndt, Sonja I, Vijai, Joseph, Conde, Lucia, Wang, Zhaoming, Yeager, Meredith, de Bakker, Paul IW, Birmann, Brenda M, Vajdic, Claire M, Foo, Jia-Nee, Bracci, Paige M, Vermeulen, Roel CH, Slager, Susan L, de Sanjose, Silvia, Wang, Sophia S, Linet, Martha S, Salles, Gilles, Lan, Qing, Severi, Gianluca, Hjalgrim, Henrik, Lightfoot, Tracy, Melbye, Mads, Gu, Jian, Ghesquières, Hervé, Link, Brian K, Morton, Lindsay M, Holly, Elizabeth A, Smith, Alex, Tinker, Lesley F, Teras, Lauren R, Kricker, Anne, Becker, Nikolaus, Purdue, Mark P, Spinelli, John J, Zhang, Yawei, Giles, Graham G, Vineis, Paolo, Monnereau, Alain, Bertrand, Kimberly A, Albanes, Demetrius, Zeleniuch-Jacquotte, Anne, Gabbas, Attilio, Chung, Charles C, Burdett, Laurie, Hutchinson, Amy, Lawrence, Charles, Montalvan, Rebecca, Liang, Liming, Huang, Jinyan, Ma, Baoshan, Liu, Jianjun, Adami, Hans-Olov, Glimelius, Bengt, Ye, Yuanqing, Nowakowski, Grzegorz S, Dogan, Ahmet, Thompson, Carrie A, Habermann, Thomas M, Novak, Anne J, Liebow, Mark, Witzig, Thomas E, Weiner, George J, Schenk, Maryjean, Hartge, Patricia, De Roos, Anneclaire J, Cozen, Wendy, Zhi, Degui, Akers, Nicholas K, Riby, Jacques, Smith, Martyn T, Lacher, Mortimer, Villano, Danylo J, Maria, Ann, Roman, Eve, Kane, Eleanor, Jackson, Rebecca D, North, Kari E, Diver, W Ryan, Turner, Jenny, Armstrong, Bruce K, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, McKay, James, Brooks-Wilson, Angela R, Zheng, Tongzhang, Holford, Theodore R, Chamosa, Saioa, Kaaks, Rudolph, Kelly, Rachel S, Ohlsson, Bodil, Travis, Ruth C, Weiderpass, Elisabete, Clavel, Jacqueline, Giovannucci, Edward, Kraft, Peter, and Virtamo, Jarmo
Published: 2014

249. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region

Author: Skibola, Christine F., Berndt, Sonja I., Vijai, Joseph, Conde, Lucia, Wang, Zhaoming, Yeager, Meredith, De Bakker, Paul I.W., Birmann, Brenda M., Vajdic, Claire M., Foo, Jia Nee, Bracci, Paige M., Vermeulen, Roel C.H., Slager, Susan L., De Sanjose, Silvia, Wang, Sophia S., Linet, Martha S., Salles, Gilles, Lan, Qing, Severi, Gianluca, Hjalgrim, Henrik, Lightfoot, Tracy, Melbye, Mads, Gu, Jian, Ghesquières, Hervé, Link, Brian K., Morton, Lindsay M., Holly, Elizabeth A., Smith, Alex, Tinker, Lesley F., Teras, Lauren R., Kricker, Anne, Becker, Nikolaus, Purdue, Mark P., Spinelli, John J., Zhang, Yawei, Giles, Graham G., Vineis, Paolo, Monnereau, Alain, Bertrand, Kimberly A., Albanes, Demetrius, Zeleniuch-Jacquotte, Anne, Gabbas, Attilio, Chung, Charles C., Burdett, Laurie, Hutchinson, Amy, Lawrence, Charles, Montalvan, Rebecca, Liang, Liming, Huang, Jinyan, Ma, Baoshan, Liu, Jianjun, Adami, Hans Olov, Glimelius, Bengt, Ye, Yuanqing, Nowakowski, Grzegorz S., Dogan, Ahmet, Thompson, Carrie A., Habermann, Thomas M., Novak, Anne J., Liebow, Mark, Witzig, Thomas E., Weiner, George J., Schenk, Maryjean, Hartge, Patricia, De Roos, Anneclaire J., Cozen, Wendy, Zhi, Degui, Akers, Nicholas K., Riby, Jacques, Smith, Martyn T., Lacher, Mortimer, Villano, Danylo J., Maria, Ann, Roman, Eve, Kane, Eleanor, Jackson, Rebecca D., North, Kari E., Diver, W. Ryan, Turner, Jenny, Armstrong, Bruce K., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, McKay, James, Brooks-Wilson, Angela R., Zheng, Tongzhang, Holford, Theodore R., Chamosa, Saioa, Kaaks, Rudolph, Kelly, Rachel S., Ohlsson, Bodil, Travis, Ruth C., Weiderpass, Elisabete, Clavel, Jacqueline, Giovannucci, Edward, Kraft, Peter, Virtamo, Jarmo, Mazza, Patrizio, Cocco, Pierluigi, Ennas, Maria Grazia, Chiu, Brian C.H., Fraumeni, Joseph F., Nieters, Alexandra, Offit, Kenneth, Wu, Xifeng, Cerhan, James R., Smedby, Karin E., Chanock, Stephen J., Rothman, Nathaniel, Skibola, Christine F., Berndt, Sonja I., Vijai, Joseph, Conde, Lucia, Wang, Zhaoming, Yeager, Meredith, De Bakker, Paul I.W., Birmann, Brenda M., Vajdic, Claire M., Foo, Jia Nee, Bracci, Paige M., Vermeulen, Roel C.H., Slager, Susan L., De Sanjose, Silvia, Wang, Sophia S., Linet, Martha S., Salles, Gilles, Lan, Qing, Severi, Gianluca, Hjalgrim, Henrik, Lightfoot, Tracy, Melbye, Mads, Gu, Jian, Ghesquières, Hervé, Link, Brian K., Morton, Lindsay M., Holly, Elizabeth A., Smith, Alex, Tinker, Lesley F., Teras, Lauren R., Kricker, Anne, Becker, Nikolaus, Purdue, Mark P., Spinelli, John J., Zhang, Yawei, Giles, Graham G., Vineis, Paolo, Monnereau, Alain, Bertrand, Kimberly A., Albanes, Demetrius, Zeleniuch-Jacquotte, Anne, Gabbas, Attilio, Chung, Charles C., Burdett, Laurie, Hutchinson, Amy, Lawrence, Charles, Montalvan, Rebecca, Liang, Liming, Huang, Jinyan, Ma, Baoshan, Liu, Jianjun, Adami, Hans Olov, Glimelius, Bengt, Ye, Yuanqing, Nowakowski, Grzegorz S., Dogan, Ahmet, Thompson, Carrie A., Habermann, Thomas M., Novak, Anne J., Liebow, Mark, Witzig, Thomas E., Weiner, George J., Schenk, Maryjean, Hartge, Patricia, De Roos, Anneclaire J., Cozen, Wendy, Zhi, Degui, Akers, Nicholas K., Riby, Jacques, Smith, Martyn T., Lacher, Mortimer, Villano, Danylo J., Maria, Ann, Roman, Eve, Kane, Eleanor, Jackson, Rebecca D., North, Kari E., Diver, W. Ryan, Turner, Jenny, Armstrong, Bruce K., Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, McKay, James, Brooks-Wilson, Angela R., Zheng, Tongzhang, Holford, Theodore R., Chamosa, Saioa, Kaaks, Rudolph, Kelly, Rachel S., Ohlsson, Bodil, Travis, Ruth C., Weiderpass, Elisabete, Clavel, Jacqueline, Giovannucci, Edward, Kraft, Peter, Virtamo, Jarmo, Mazza, Patrizio, Cocco, Pierluigi, Ennas, Maria Grazia, Chiu, Brian C.H., Fraumeni, Joseph F., Nieters, Alexandra, Offit, Kenneth, Wu, Xifeng, Cerhan, James R., Smedby, Karin E., Chanock, Stephen J., and Rothman, Nathaniel
Published: 2014

250. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.

Author: Cerhan, James R, Cerhan, James R, Berndt, Sonja I, Vijai, Joseph, Ghesquières, Hervé, McKay, James, Wang, Sophia S, Wang, Zhaoming, Yeager, Meredith, Conde, Lucia, de Bakker, Paul IW, Nieters, Alexandra, Cox, David, Burdett, Laurie, Monnereau, Alain, Flowers, Christopher R, De Roos, Anneclaire J, Brooks-Wilson, Angela R, Lan, Qing, Severi, Gianluca, Melbye, Mads, Gu, Jian, Jackson, Rebecca D, Kane, Eleanor, Teras, Lauren R, Purdue, Mark P, Vajdic, Claire M, Spinelli, John J, Giles, Graham G, Albanes, Demetrius, Kelly, Rachel S, Zucca, Mariagrazia, Bertrand, Kimberly A, Zeleniuch-Jacquotte, Anne, Lawrence, Charles, Hutchinson, Amy, Zhi, Degui, Habermann, Thomas M, Link, Brian K, Novak, Anne J, Dogan, Ahmet, Asmann, Yan W, Liebow, Mark, Thompson, Carrie A, Ansell, Stephen M, Witzig, Thomas E, Weiner, George J, Veron, Amelie S, Zelenika, Diana, Tilly, Hervé, Haioun, Corinne, Molina, Thierry Jo, Hjalgrim, Henrik, Glimelius, Bengt, Adami, Hans-Olov, Bracci, Paige M, Riby, Jacques, Smith, Martyn T, Holly, Elizabeth A, Cozen, Wendy, Hartge, Patricia, Morton, Lindsay M, Severson, Richard K, Tinker, Lesley F, North, Kari E, Becker, Nikolaus, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, Lightfoot, Tracy, Crouch, Simon, Smith, Alex, Roman, Eve, Diver, W Ryan, Offit, Kenneth, Zelenetz, Andrew, Klein, Robert J, Villano, Danylo J, Zheng, Tongzhang, Zhang, Yawei, Holford, Theodore R, Kricker, Anne, Turner, Jenny, Southey, Melissa C, Clavel, Jacqueline, Virtamo, Jarmo, Weinstein, Stephanie, Riboli, Elio, Vineis, Paolo, Kaaks, Rudolph, Trichopoulos, Dimitrios, Vermeulen, Roel CH, Boeing, Heiner, Tjonneland, Anne, Angelucci, Emanuele, Di Lollo, Simonetta, Rais, Marco, Birmann, Brenda M, Cerhan, James R, Cerhan, James R, Berndt, Sonja I, Vijai, Joseph, Ghesquières, Hervé, McKay, James, Wang, Sophia S, Wang, Zhaoming, Yeager, Meredith, Conde, Lucia, de Bakker, Paul IW, Nieters, Alexandra, Cox, David, Burdett, Laurie, Monnereau, Alain, Flowers, Christopher R, De Roos, Anneclaire J, Brooks-Wilson, Angela R, Lan, Qing, Severi, Gianluca, Melbye, Mads, Gu, Jian, Jackson, Rebecca D, Kane, Eleanor, Teras, Lauren R, Purdue, Mark P, Vajdic, Claire M, Spinelli, John J, Giles, Graham G, Albanes, Demetrius, Kelly, Rachel S, Zucca, Mariagrazia, Bertrand, Kimberly A, Zeleniuch-Jacquotte, Anne, Lawrence, Charles, Hutchinson, Amy, Zhi, Degui, Habermann, Thomas M, Link, Brian K, Novak, Anne J, Dogan, Ahmet, Asmann, Yan W, Liebow, Mark, Thompson, Carrie A, Ansell, Stephen M, Witzig, Thomas E, Weiner, George J, Veron, Amelie S, Zelenika, Diana, Tilly, Hervé, Haioun, Corinne, Molina, Thierry Jo, Hjalgrim, Henrik, Glimelius, Bengt, Adami, Hans-Olov, Bracci, Paige M, Riby, Jacques, Smith, Martyn T, Holly, Elizabeth A, Cozen, Wendy, Hartge, Patricia, Morton, Lindsay M, Severson, Richard K, Tinker, Lesley F, North, Kari E, Becker, Nikolaus, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, Staines, Anthony, Lightfoot, Tracy, Crouch, Simon, Smith, Alex, Roman, Eve, Diver, W Ryan, Offit, Kenneth, Zelenetz, Andrew, Klein, Robert J, Villano, Danylo J, Zheng, Tongzhang, Zhang, Yawei, Holford, Theodore R, Kricker, Anne, Turner, Jenny, Southey, Melissa C, Clavel, Jacqueline, Virtamo, Jarmo, Weinstein, Stephanie, Riboli, Elio, Vineis, Paolo, Kaaks, Rudolph, Trichopoulos, Dimitrios, Vermeulen, Roel CH, Boeing, Heiner, Tjonneland, Anne, Angelucci, Emanuele, Di Lollo, Simonetta, Rais, Marco, and Birmann, Brenda M
Abstract: Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of 3 new genome-wide association studies (GWAS) and 1 previous scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of 9 promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (EXOC2; P = 2.33 × 10(-21)), rs2523607 at 6p21.33 (HLA-B; P = 2.40 × 10(-10)), rs79480871 at 2p23.3 (NCOA1; P = 4.23 × 10(-8)) and two independent SNPs, rs13255292 and rs4733601, at 8q24.21 (PVT1; P = 9.98 × 10(-13) and 3.63 × 10(-11), respectively). These data provide substantial new evidence for genetic susceptibility to this B cell malignancy and point to pathways involved in immune recognition and immune function in the pathogenesis of DLBCL.
Published: 2014

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

671 results on '"Ghesquières, Hervé"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources